Stacy Ardoin, MD

Physician, Professor

Rheumatology

Contact our office

614-293-8000

Appointments cannot be scheduled directly with this provider.

Conditions and expertise

  • Rheumatology
  • Vasculitis
  • Rheumatoid Vasculitis
  • Mixed Connective Tissue Disease
  • Lupus Vasculitis, Central Nervous System
  • Lupus Nephritis

View all conditions

Locations

  • University Hospital – Rhodes Hall

View location details

Academics and research

Department: Internal Medicine

View my research

About

Gender
Female

Biography

I am board-certified in both adult and pediatric rheumatology. I see pediatric patients at Nationwide Children's Hospital and adult patients here in The Ohio State University Rheumatology Clinic and in The Ohio State University Lupus Clinic. Dr. Ardoin provides comprehensive rheumatologic care to patients with lupus, vasculitis, rheumatoid arthritis, scleroderma, myositis and other rheumatologic conditions.

Highlights

  • Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2014-2018
  • Named to Castle Connolly's Regional Top Doctors list

Conditions and expertise

  • Arthritis, Juvenile Rheumatoid
  • Cutaneous Lupus Erythematosus
  • Lupus Nephritis
  • Lupus Vasculitis, Central Nervous System
  • Mixed Connective Tissue Disease
  • Rheumatoid Vasculitis
  • Rheumatology
  • Systemic Lupus Erythematosus
  • Vasculitis

Locations

Please note: Not all physicians schedule patients at each listed location.

Credentials

Education

Doctor of Medicine (MD)
Ohio State University College of Medicine, Columbus, OH, United States
8/23/1993 - 6/13/1997

Certifications

  • American Board of Internal Medicine/Rheumatology
    11/20/2006
  • American Board of Pediatrics/Rheumatology
    11/16/2006

Academics and research

A multi-center group of investigators and I completed an NIH-funded Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial. Systemic lupus erythematosus (SLE) significantly increases the risk of developing cardiovascular disease including stroke and heart attack. As available SLE therapies have improved, people with SLE are living longer, and the problem of cardiovascular disease has emerged as a very important long-term concern.

Children and adolescents with lupus are at especially high risk as they face a longer burden of disease. Statins are known to prevent atherosclerosis, heart attack and stroke but their effectiveness in SLE, particularly in children and adolescents with SLE, remains unknown. In the APPLE trial, 210 children and adolescents from 21 sites in North America were randomized to receive atorvastatin or placebo for three years in addition to standard SLE care. Carotid intimal medial thickening (CIMT) was measured to determine whether atorvastatin reduced atherosclerosis development as measured by progression of CIMT.

The APPLE trial did not meet its primary endpoint but did show a trend of less CIMT progression in the atorvastatin-treated participants. Atorvastatin also effectively lowered LDL and c-reactive protein. Atorvastatin was well tolerated without safety concerns. An important observation of the APPLE trial was that the placebo group showed definite progression in CIMT, providing clear evidence that atherosclerosis does begin and progress in children and adolescents with SLE. Results from the APPLE study do not provide support for routine use of statins in children and adolescents with SLE. Further analysis may identify subgroups that may benefit. I am currently conducting the following clinical trials:

  • Laquinimod to Treat Lupus Arthritis, Sponsor: TEVA
  • Assessment of Transition Readiness, Sponsor: Investigator Initiated
  • Lupus Nephritis Histology, Sponsor: Cincinnati Children's Hospital
  • Myocardial Inflammation in SLE, Sponsor: Investigator Initiated
  • Estrogen Effects in Autoimmunity, Sponsor: Investigator Initiated
  • Impact of Fragmentation of Care in Lupus, Sponsor: Investigator Initiated
  • Lupus/Vasculitis Clinic Registry, Sponsor: Investigator Initiated

Research interests

  • Lupus
  • Atherosclerosis in Children and Adults with Lupus
  • Neuropsychiatric Manifestations of SLE
  • Transition to Adult Care

Additional Research Interests

My clinical research focuses on optimal treatment and longterm outcomes of adults and children with lupus. She is particularly interested in discovering ways to prevent the development of atherosclerosis in children and adults with lupus. My other research interests include neuropsychiatric manifestations of SLE and the transition from child-centered to adult-centered medical care.

Academic information

Department:
Internal Medicine
Division:
Rheumatology - Immunology

More about my research

Ratings and reviews

The overall patient satisfaction rating is an average of all patient responses to the six doctor communication related questions shown below from the Clinician and Group Consumer Assessment of Healthcare Providers and Systems survey. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page.

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of Ohio State Wexner Medical Center.

49 Patient Satisfaction Reviews

4.9 out of 5 overall

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.

As of 11/3/2025, Stacy Ardoin has reported no relationships with companies or entities.

Subscribe. Get just the right amount of health and wellness in your inbox.